Introduction
============

Impetigo is a bacterial infection that can be caused by Staphylococcus aureus (*S. aureus*) \[[@b1-dp0503a09]\]. Herpes zoster is a viral infection caused by varicella-zoster virus \[[@b2-dp0503a09]\]. Occasionally, non-viral conditions---including bacterial infections---can morphologically mimic herpes zoster by presenting with skin lesions in a dermatomal distribution \[[@b3-dp0503a09]\]. A man who presented with zosteriform facial skin lesions of impetigo is described and the clinical features of previously reported patients with dermatomal *S. aureus* infection are summarized.

Case report
===========

A 66-year-old healthy afebrile man presented for evaluation of skin lesions that had developed on the left side of his face. His cutaneous past medical history was remarkable for cryotherapy-treated actinic keratoses, excision of two basal cell carcinomas (on the left chest in 2004 and the right cheek in 2009), and genital herpes simplex virus type 2 infection. He had chicken pox as a child and no episode of herpes zoster; he had received the varicella vaccine 2 years ago.

A week earlier, he noticed that facial skin lesions began to appear. Initially the site was pruritic and then a crust would develop; there were no blisters. The lesions were first noted on the left side of his chin; subsequently, they developed on his left cheek and left neck, near his jaw. Based on the distribution and morphology of his skin lesions, his wife diagnosed him to have a shingles.

Cutaneous examination showed crusted, eroded and intact, erythematous papules and nodules---ranging in size from 3 to 5 mm in diameter---restricted to only the left side of his face. There were about 12 lesions. They were located on his chin, cheek, and neck in a distribution that corresponded to the third division of the fifth cranial nerve ([Figure 1](#f1-dp0503a09){ref-type="fig"}).

The unilateral and dermatome location of the skin lesions raised the possibility of herpes zoster. However, the appearance of the individual crusted erosions was consistent with impetigo. Additional laboratory studies were performed and he was empirically treated for both herpes zoster (with 1 gram of oral valacyclovir three times daily for 10 days) and impetigo (with 300 mg of oral cefdinir twice daily for 10 days and topical mupirocin 2% ointment three times daily for 10 days).

All of the facial skin lesions resolved within 1 week; no residual crusts were present at his 1-month follow up examination. A Tzanck smear taken from one of the lesions at presentation was negative for multinucleated epidermal giant cells. In addition, not only the direct fluorescent absorption studies, but also the viral cultures were negative for both herpes zoster virus and herpes simplex virus. The bacterial culture from a crusted erosion was positive for methicillin susceptible *S. aureus*; the bacteria was also susceptible to cefazolin.

Discussion
==========

Non-bullous impetigo is caused by either *S. aureus* or *Streptococcus pyogenes*. It typically presents as a superficial ulcer covered by a purulent exudate that dries into an adherent yellow to honey-colored crust. Lesions are frequently found on the face and extremities. Satellite lesions are common, resulting from self-inoculation \[[@b1-dp0503a09],[@b4-dp0503a09]--[@b6-dp0503a09]\].

Herpes zoster occurs when there is reactivation of a latent varicella-zoster infection. Skin lesions typically present as unilateral, erythematous-based vesicles in a dermatomal distribution. Less commonly, disseminated herpes zoster can present as multiple, widely distributed, individual vesicles---with or without---associated dermatomal skin involvement. In addition to a positive viral culture for varicella-zoster virus, bacterial culture can concurrently be positive for *S. aureus* when the vesicular, ulcerated or crusted lesions become colonized or secondarily infected by the bacterial organism \[[@b2-dp0503a09],[@b7-dp0503a09]--[@b9-dp0503a09]\].

Zosteriform impetigo represents the development of nonbullous impetigo, to date caused by *S. aureus* infection, in which the cutaneous lesions appear in a dermatomal distribution. Varicella-zoster virus is absent from the bacterial skin lesions. In addition to the reported patient, zosteriform *S. aureus* cutaneous infection has been described in 3 other individuals ([Table 1](#t1-dp0503a09){ref-type="table"}) \[[@b3-dp0503a09],[@b10-dp0503a09]--[@b13-dp0503a09]\]; however, one might speculate that zosteriform cutaneous staphylococcal infection is probably more common than the paucity of reported individuals would suggest.

There were 3 men and 1 girl; the latter was 17 years old. The men ranged in age from 63 to 76 years; the median age was 66 years. Dermatomes were affected equally on the right and left side of the body; two of the men had involvement of the same area: the facial skin innervated by the mandibular branch of the trigeminal nerve. The infection presented with clinical features of furunculosis (2 patients), impetigo (1 patient) or both (1 patient). Bacterial cultures of the skin lesion were positive for either methicillin-susceptible (2 patients) or methicillin-resistant (1 patient) *S. aureus* \[[@b14-dp0503a09]\]. Viral culture, at this time of *S. aureus* infection, was negative for varicella-zoster virus; in addition, 3 of the 4 patients did not have a history of clinically significant herpes zoster (either in the affected area or elsewhere on their body). The bacterial infection was successfully treated with oral antibiotic in all patients; however one man experienced 2 recurrences in the same area.

Wolf's isotopic response designates the occurrence of a new cutaneous disorder at the location of a previously healed skin disease \[[@b15-dp0503a09]\]. It was originally termed "isoloci response" by Wolf and Wolf in 1985 \[[@b16-dp0503a09]\]. A decade later, Ruocco suggested changing the name to "isotopic response" \[[@b10-dp0503a09],[@b17-dp0503a09],[@b18-dp0503a09]\]. However, since the latter designation generated hundreds of references linked with radioactive isotopes during computer-obtained literature searches, it was subsequently changed to "Wolf's isotopic response" \[[@b19-dp0503a09]\].

Several types of postherpetic isotopic responses have been observed following either herpes simplex virus or varicella-zoster virus infections. These not only include fungal and other viral infections, but also acneiform lesions, dysimmune reactions, granulomatous reactions, leukemia and lymphomatous infiltrates, malignant tumors and other conditions \[[@b3-dp0503a09],[@b11-dp0503a09],[@b12-dp0503a09]\]. Bacterial infections, such as furunculosis and *S. aureus*-associated nonbullous impetigo have each only been observed in 4 individuals ([Table 1](#t1-dp0503a09){ref-type="table"}) \[[@b3-dp0503a09],[@b10-dp0503a09]--[@b13-dp0503a09]\].

A cutaneous immunocompromised district is an area of skin that---for either genetic or acquired reasons---is more vulnerable than the rest of the individual's body. This vulnerable site often facilitates the onset of skin disorders or immunity-related eruptions at that area because of the local dysregulation of immune control. The immunocompromised district in dermatology is a designation that is intended to include all possible etiologies potentially involved in a local immune destabilization of the affected area of mucosa or skin \[[@b20-dp0503a09],[@b21-dp0503a09]\].

Zosteriform impetigo is favored to represent Wolf's postherpetic isotopic response in a cutaneous immunocompromised district \[[@b3-dp0503a09],[@b8-dp0503a09],[@b11-dp0503a09],[@b12-dp0503a09]\]. The absence of a definitive history of preceding varicella-zoster virus infection in 75 percent of the individuals (3 of the 4 patients) may reflect a prior subclinical varicella-zoster virus infection, such as an episode of asymptomatic zoster sine herpete \[[@b7-dp0503a09],[@b8-dp0503a09]\]. Alternatively, and often similar in presentation with a dermatomal distribution, is the possibility of a Blascho linear arrangement due to skin mosaicism \[[@b22-dp0503a09]\].

Conclusion
==========

Impetigo and herpes zoster are common bacterial and viral infections, respectively. Concurrent *S. aureus* infection or impetinization of varicella-zoster virus infectious skin lesions may occur; however, cultures of the skin lesions are typically positive for both bacteria and virus. However, similar to the described patient, the skin lesions of zosteriform impetigo are only culture positive for *S. aureus*; viral studies---including Tzanck smear, culture, direct fluorescent absorption, and polymerase chain reaction---are negative. Wolf's isotopic postherpetic response in a cutaneous immunocompromised district is not uncommon; however, bacterial infection is seldom reported in this setting. Some of individuals with zosteriform cutaneous staphylococcal infections did not recall a prior herpes zoster infection at that site raising the possibility that they had previously experienced an episode of asymptomatic zoster sine herpete. Similar to non-dermatomal *S. aureus* infection, zosteriform impetigo promptly responded to antibiotics to which the bacteria are susceptible.
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###### 

Distant (A) and closer (B and C) views of zosteriform impetigo located on facial skin innervated by the mandibular branch of the left trigeminal nerve; the lesion appear as crusted, eroded and intact, erythematous papules and nodules on the left side of the chin (B) and neck (C). \[Copyright: ©2015 Cohen.
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###### 

Characteristics of patients with zosteriform cutaneous staphylococcal infections \[[a](#tfn1-dp0503a09){ref-type="table-fn"},[b](#tfn2-dp0503a09){ref-type="table-fn"}\]

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **C**   **A**\    **Location**                   **Morphology**                                                        **CP**   **Bact**\   **VC**   **Prior**\                                         **Other**\                                                      **Tx**                                          **Ref**
          **Ra**\                                                                                                                 **cult**             **VZV**                                            **conditions**                                                                                                  
          **S**                                                                                                                                                                                                                                                                                                           
  ------- --------- ------------------------------ --------------------------------------------------------------------- -------- ----------- -------- -------------------------------------------------- --------------------------------------------------------------- ----------------------------------------------- ---------
  1       17\       Breast, upper flank, & back\   Multiple erythematous pustules, papules, & nodules                    I & F    MRSA        \-       \-                                                 MEN 2B\                                                         [\[c\]](#tfn3-dp0503a09){ref-type="table-fn"}   13C2
          W\        R T4                                                                                                                                                                                  Metastatic medullary thyroid cancer                                                                             
          F                                                                                                                                                                                                                                                                                                               

  2       63\       Abdomen\                       Tender red nodules × 3 with intact, ulcerated, and pustular centers   F        MSSA        \-       \-                                                 SCC: L temple                                                   [\[d\]](#tfn4-dp0503a09){ref-type="table-fn"}   13C1
          W\        R T11                                                                                                                                                                                                                                                                                                 
          M                                                                                                                                                                                                                                                                                                               

  3       66\       Face\                          12 crusted, eroded & intact, red papules & nodules                    I        MSSA        \-       \-                                                 AK\                                                             [\[e\]](#tfn5-dp0503a09){ref-type="table-fn"}   CR
          W\        L CNV-3                                                                                                                                                                               BCC × 2: R cheek & L chest\                                                                                     
          M                                                                                                                                                                                               HSV 2: genital                                                                                                  

  4       76\       Face\                          Furuncles [\[f\]](#tfn6-dp0503a09){ref-type="table-fn"}               F        ND          ND       \+ [\[f\]](#tfn6-dp0503a09){ref-type="table-fn"}   Colon carcinoma [\[f\]](#tfn6-dp0503a09){ref-type="table-fn"}   [\[f\]](#tfn6-dp0503a09){ref-type="table-fn"}   10
          ND\       L CNV-3                                                                                                                                                                                                                                                                                               
          M                                                                                                                                                                                                                                                                                                               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: A, age (in years); AK, actinic keratosis; Bact cult, bacterial culture; BCC, basal cell carcinoma; C, case; CNV-3, third division (mandibular branch) of fifth cranial (trigeminal) nerve dermatome; CP, clinical presentation; CR, current report; F, furunculosis; HSV 2, herpes simplex virus, type 2 infection; I, impetigo; L, left; MEN 2B, multiple endocrine neoplasia, type 2B (also known as either mucosal neuroma syndrome or multiple endocrine adenomatosis, type 2B; an autosomal dominant syndrome characterized by medullary thyroid carcinoma, pheochromocytoma, multiple mucosal neuromas and intestinal ganglioneuromas, and often a marfanoid habitus and other skeletal abnormalities); MRSA; methicillin-resistant Staphylococcus aureus; MSSA, methicillin susceptible Staphylococcus aureus; ND, not done; R, right; Ra, race; Ref, references; S, sex; SCC, squamous cell carcinoma; T, thoracic dermatome; TMP/SMX DS, trimethoprim/sulfamethoxazole double strength; Tx, treatment; VC, viral culture (for VZV); VZV, varicella-zoster virus infection (herpes zoster); &, and; −, negative or none, + positive, %, percent.

Furunculosis has been reported as a postherpetic isotopic response in 3 individuals; however, for 2 of the people, it is not definitively defined whether the herpetic infection was caused by herpes simplex virus or varicella-zoster virus in each of these individuals \[[@b5-dp0503a09],[@b10-dp0503a09],[@b11-dp0503a09],[@b12-dp0503a09]\].

Treatment included oral TMP/SMX DS twice daily for 15 days; topical therapy included cleaning with povodine iodine (betadine) 10% cleanser and mupirocin 2% ointment 3 times daily to lesions, nostrils and umbilicus.

Treatment included oral TMP/SMX DS twice daily for 4 weeks; topical therapy included cleaning with chlorhexidine (hibiclens) 4% solution and mupirocin 2% ointment 3 times daily to lesions and nostrils.

Treatment included oral cefdinir 300 mg twice daily for 10 days; topical therapy included mupirocin 2% ointment 3 times daily to lesions.

The diagnosis of colon cancer occurred at the same time as his initial episode of herpes zoster. The herpes zoster virus infection occurred 1 month prior to his zosteriform furunculosis and presented as numerous small, solitary and grouped vesicles that were successfully treated with oral acyclovir 800 mg 5 times daily. He had 3 episodes of zosteriform furunculosis; the second and third episodes occurred 2 months and 5 months after the initial episode. Each episode was confined to the same area of his face and the "furuncles were not arranged in groups, thus a recurrent herpes simplex could easily be excluded clinically." The initial and second episodes were each treated with oral cefaclor 500 mg twice daily for 5 days.
